Establishment Labs Holdings Inc. (NASDAQ:ESTA) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) have received an average rating of "Moderate Buy" from the six research firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $57.40.

ESTA has been the subject of several recent research reports. Stephens restated an "overweight" rating and set a $52.00 target price on shares of Establishment Labs in a report on Thursday, March 6th. Needham & Company LLC assumed coverage on shares of Establishment Labs in a research note on Monday, April 14th. They set a "hold" rating for the company.

Hedge Funds Weigh In On Establishment Labs

Institutional investors have recently modified their holdings of the company. Barclays PLC increased its position in shares of Establishment Labs by 9,643.3% during the third quarter. Barclays PLC now owns 31,471 shares of the company's stock valued at $1,362,000 after purchasing an additional 31,148 shares during the period. Assenagon Asset Management S.A. bought a new position in shares of Establishment Labs in the fourth quarter worth about $12,898,000. R Squared Ltd bought a new stake in shares of Establishment Labs during the fourth quarter worth $36,000. Handelsbanken Fonder AB lifted its position in Establishment Labs by 32.3% during the 4th quarter. Handelsbanken Fonder AB now owns 8,200 shares of the company's stock valued at $378,000 after purchasing an additional 2,000 shares during the period. Finally, Raymond James Financial Inc. bought a new position in Establishment Labs in the fourth quarter valued at approximately $5,494,000. Institutional investors own 72.91% of the company's stock.

Establishment Labs Stock Down 2.3 %

Shares of NASDAQ:ESTA traded down $0.79 on Friday, hitting $34.01. 485,256 shares of the company's stock were exchanged, compared to its average volume of 466,896. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62. Establishment Labs has a 1-year low of $26.56 and a 1-year high of $60.12. The firm's 50-day moving average is $34.83 and its 200 day moving average is $38.52. The company has a market capitalization of $981.05 million, a PE ratio of -13.18 and a beta of 0.73.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.13. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The company had revenue of $41.38 million for the quarter, compared to analyst estimates of $41.15 million. During the same quarter in the previous year, the company posted ($0.58) earnings per share. The firm's revenue was up 11.3% compared to the same quarter last year. Sell-side analysts predict that Establishment Labs will post -2.41 EPS for the current year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.